Bayer AG (BAY.F) Halts Study of Hemophilia Therapy BAY 86-6150 Due to Safety Concerns
5/6/2013 8:37:54 AM
Staying up-to-date has never been simpler. Sign up for the free
GenePool newsletter today!
Bayer said its HealthCare division stopped a Phase II/III study testing its experimental treatment BAY 86-6150 on certain haemophilia A and B patients due to safety concerns.
Help employers find you! Check out all the jobs and post your resume.
comments powered by